Drug Trial Radar · NCT03536767
Open-Label Study of AG10 in Patients With Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
47
Actual
Start
Aug 8, 2018
Primary completion
Sep 15, 2025
Study completion Sep 15, 2025
Sponsor
- Lead sponsor
- Eidos Therapeutics, a BridgeBio companyIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of acoramidis administered on a background of stable heart failure therapy.
Conditions
- Amyloid Cardiomyopathy
Interventions
AcoramidisDrug
Acoramidis 800 mg twice daily, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Summary of Treatment-Emergent Adverse Events.Time frame: From the first dose of study drug until 30 days after the last dose of study drug. (Maximum exposure reported 84.1 months).
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Stanford University
Stanford, California
Yale University
New Haven, Connecticut
Northwestern University
Chicago, Illinois
Brigham and Women's Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Columbia University
New York, New York
Oregon Health & Science University
Portland, Oregon
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.